Misfortunes do not come in pairs in patients with active moderate-to-severe Graves' orbitopathy

被引：1
|
作者：
Sawicka-Gutaj, Nadia [1 ]
Gruszczynski, Dawid [1 ]
Zawalna, Natalia [1 ]
Nijakowski, Kacper [2 ]
Fichna, Marta [1 ]
Ruchala, Marek [1 ]
机构：
[1] Poznan Univ Med Sci, Dept Endocrinol Metab Disorders & Internal Med, Ul Przybyszewskiego 49, PL-60335 Poznan, Poland
[2] Poznan Univ Med Sci, Dept Conservat Dent & Endodont, Poznan, Poland
来源：
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ | 2024年 / 134卷 / 06期
关键词：
EUROPEAN GROUP; ZNT8;
D O I：
10.20452/pamw.16773
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Misfortunes do not come in pairs in patients with active moderate-to-severe Graves' orbitopathy (vol 134, 16773, 2024)
    不详
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2024, 134 (7-8):
  • [2] What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail?
    Bartalena, Luigi
    CLINICAL ENDOCRINOLOGY, 2010, 73 (02) : 149 - 152
  • [3] Is Radioactive Iodine Contraindicated in Patients with Moderate-to-Severe and Active Graves' Orbitopathy?
    Bartalena, Luigi
    Tanda, Maria Laura
    THYROID, 2025,
  • [4] Role of teprotumumab in the treatment of active moderate-to-severe Graves' orbitopathy
    Bartalena, Luigi
    EUROPEAN THYROID JOURNAL, 2022, 11 (06)
  • [5] Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves' Orbitopathy
    Bartalena, Luigi
    Wiersinga, Wilmar M.
    EUROPEAN THYROID JOURNAL, 2020, 9 (SUPPL 1) : 3 - 16
  • [6] Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?
    Piantanida, E.
    Bartalena, L.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2017, 40 (08): : 885 - 887
  • [7] Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves’ orbitopathy?
    E. Piantanida
    L. Bartalena
    Journal of Endocrinological Investigation, 2017, 40 : 885 - 887
  • [8] Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy
    Campi, Irene
    Vannucchi, Guia
    Muller, Ilaria
    Lazzaroni, Elisa
    Curro, Nicola
    Dainese, Martina
    Montacchini, Benedetta
    Covelli, Danila
    Guastella, Claudio
    Pignataro, Lorenzo
    Fugazzola, Laura
    Arosio, Maura
    Salvi, Mario
    FRONTIERS IN ENDOCRINOLOGY, 2022, 12
  • [9] Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves' Orbitopathy
    Lin, Miaoli
    Mao, Yuxiang
    Ai, Siming
    Liu, Guangming
    Zhang, Jian
    Yan, Jianhua
    Yang, Huasheng
    Li, Aimin
    Zou, Yusha
    Liang, Dan
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015
  • [10] Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy
    Marcocci, Claudio
    Marino, Michele
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 26 (03) : 325 - 337
12345